About Us


BioCheck, located in the San Francisco Bay Area, was founded in April 1997, to develop and manufacture high-quality enzyme immunoassay test kits for the worldwide biomedical, pharmaceutical and scientific research markets. The founders have brought over four decades of experience, enabling BioCheck to quickly provide reliable and sensitive products to its customers.

Every BioCheck EIA kit is manufactured according to U.S. Food and Drug Administration (FDA) Good Manufacturing Practice and ISO standards in our 20,000 square foot facility in South San Francisco, California. At the present time, the company manufactures over 40 EIA test kits, of which 17 have been FDA cleared. And the test kits are distributed across the globe.

BioCheck is also a leading developer of immunodiagnostics with extensive experience bringing new IVD products to market, now including development for ultra-sensitive Simoa TM assays (single molecule array) and diagnostic test kits on MS-Fast chemiluminescent platform. BioCheck is currently commercializing the MS-FAST analyzer (automated chemiluminescent immunoassay system) and associated COVID-19 test kits to allow convenient, instant, and accurate diagnosis of the disease with a bench top instrument.